Research: Study for Medication at University of Louisville

This announcement has been posted as a courtesy by the National Fragile X Foundation (NFXF) on behalf of Kosair Charities Pediatric Clinical Research Unit at the University of Louisville. The announcement and the parties conducting and sponsoring the research meet guidelines established by the NFXF regarding relevancy and appropriateness to Fragile X. The NFXF takes no position and makes no claims as to the potential benefits of the study including those studies involving medications, and cannot be responsible for any outcomes, lack of outcomes or unintended side effects. Your name or other personal information have not been shared with the researchers/company/institution. If interested in participating in this research, it is your responsibility to use the contact information in this announcement. Additional opportunities for being part of research studies can be found at

Do you have Fragile X syndrome? Are you the parent or caregiver of a person with Fragile X syndrome, or know someone who is?

The Kosair Charities Pediatric Clinical Research Unit at the University of Louisville invites adolescents and adults with Fragile X Syndrome to take part in a research study for a medication that is being developed to treat the symptoms of Fragile X Syndrome. We hope to learn more about its safety, how well your body manages it (tolerability), and how much medicine is in your body (pharmacokinetics).

This study is being sponsored (organized and paid for) by the pharmaceutical company Hoffmann-La Roche, and more information about this clinical trial can be found on the website at It has been reviewed and approved by the University of Louisville Institutional Review Board (IRB # 12.0336), and is being conducted at U of L under the direction of Dr. Lisa Craft.

Both males and females between 16 and 50 years old can take part. This study is placebo controlled, which means that some patients will get the study medication, and some patients will get a placebo, which is like a “sugar pill” (does not contain active ingredient). After a screening period to determine eligibility, the study will last about 4 months. Throughout the study, there will be some psychological assessments, as well as some lab work and other safety monitoring assessments. Patients will be compensated for time/travel.

If interested, please contact:

Carrie Schanie, RN
(502) 629-6802

Kosair Charities Pediatric Clinical Research Unit
231 E. Chestnut Street,
N-97 (2 East)
Louisville, KY 40202
(502) 629-5820 or (502) 620-0000 [pager]

IRB # 12.0336